SPRY vs HALO vs ABBV vs ALNY

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus -5. 5% for ARS Pharmaceuticals, Inc. (SPRY). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 0x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate Halozyme Therapeutics, Inc. (HALO) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 25. 0x versus Alnylam Pharmaceuticals, Inc. at 126. 6x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +129. 4%, compared to -67. 0% for ARS Pharmaceuticals, Inc. (SPRY). Over 10 years, the gap is even starker: HALO returned +559. 7% versus SPRY's -65. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus ARS Pharmaceuticals, Inc. 's 1. 47β — meaning SPRY is approximately 433% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus -5. 5% for ARS Pharmaceuticals, Inc. (SPRY). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -23. 3% for ARS Pharmaceuticals, Inc.. Over a 3-year CAGR, SPRY leads at 300. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -203. 3% for ARS Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -212. 9% for SPRY. At the gross margin level — before operating expenses — ALNY leads at 81. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 0x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 32. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SPRY: 191. 8% to $25. 50.

In this comparison, ABBV (3.

3% yield) pays a dividend. SPRY, HALO, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, SPRY: -65. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SPRY is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; ALNY is a mid-cap high-growth stock. ABBV pays a dividend while SPRY, HALO, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.